Projects per year
Creating an evidence base for clinical care: A randomized controlled study examining the efficacy of the low FODMAP diet for the relief of gastrointestinal symptoms in endometriosis.
1/06/20 → 31/05/25
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.
Burgell, R. & McKenzie, J.
26/03/20 → 31/12/25
Prevalence of sucrase-isomaltase genetic hypomorphic variants in patients with irritable bowel syndrome in Australia
1/01/20 → 31/12/20
RECIPE: Randomised controlled trial (RCT) of ROTEM-guided blood component administration versus standard of care in patients with cirrhosis and coagulopathy undergoing invasive procedures.
5/12/19 → 31/08/21
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation
Roberts, S. & Lewis, P.
8/11/19 → 30/06/23
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation. Clinical study No. MGL-3196-11.
24/10/19 → 31/12/24
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma.
Roberts, S., Lewis, P., George, J., Zekry, A., O'Beirne, J., Tse, E., McLachlan, S., Eastgate, M., Ananda, S. S. & Davison, S.
24/09/19 → 30/09/23
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.
Burgell, R. & Hogg, J.
9/09/19 → 31/12/24
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).
17/05/19 → 31/05/23
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1).
Roberts, S. & Lewis, P.
24/01/19 → 30/04/23
Open Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 +/- ribavirin (RBV) in the treatment of Hepatitis C G1 and 4, in patients either eligible for liver transplant (HCC) or curative therapy or non-eligible for curative therapy but clinically stable disease post local resection, embolization or ablative therapy: HATCHeT Study - HepATocellular Cancer Hcv Therapy Study.
Kemp, W. & Mitchell, J.
7/08/18 → 7/08/23
FODMAP: Changing therapeutic paradigms for intestinal health: Diet as a therapeutic strategy in Gastroenterology.
1/01/18 → 31/12/22